Epizyme stock: buy or sell?

EPZM stock price: $13.28 -2.21% At close on August 22nd, 2019

Updated on:
August 22nd, 2019


Epizyme shares dropped -2.21% to $13.28 today. On Friday EPZM rocketed an extraordinary 6.49%.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States.

Should I buy Epizyme stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Following a trading strategy helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, Epizyme stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean EPZM will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Epizyme stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we detected 6 ratings published for EPZM stock in the last month.

The general sentiment of these ratings is bullish for EPZM stock, with 6 positive ratings.
Is EPZM a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-6-24HC Wainwrightn/aBuy
2019-1-7Leerink SwannMarket PerformOutperform

Epizyme stock analysis

Daily outlook

Epizyme shares dropped -2.21% to $13.28 today.

Epizyme closed today at $13.28 and dropped a tragic -2.21%. On April, SMA100d and SMA200d crossed up triggering a rise of 4.73%. Since last Friday when EPZM stock price broke up the SMA100d line, it gained $0.45 (3.51%).

EPZM stock chart (daily)

Weekly outlook

After boosting an amazing 16.18% in a week last week, Epizyme closed this week at $13.28 and eased a tragic -3.21%. Early August EPZM plummed a dreadful -6.09% in just one week.

Since early April when SMA20w and SMA40w crossed up, EPZM price slipped $-0.36 per share (-2.64%). Since early February when EPZM stock price broke up the SMA40w line, it gained $2.61 (24.46%).

EPZM stock chart (weekly)

Epizyme stock price history

Epizyme IPO was on May 31st, 2013 at $20.00 per share1. Since then, EPZM stock declined a -33.60%, with a yearly average of -5.60%.

1: Adjusted price after possible price splits or reverse-splits.

Epizyme stock historical price chart

EPZM stock reached 52-week highs on June at $16.59, and all-time highs 2013-07-17 with a price of 45.72.

Epizyme stock price target is $20.50

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we found 4 price forecasts for Epizyme stock:
EPZM stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-6-24HC WainwrightSet Price Targetn/a$25.00-
2019-2-27OppenheimerLowers Target$27.00$18.00-33.3%
(in average)$27.00$20.50-24.0%
The price target for Epizyme stock is $20.50, moving in a range between $25.00 and $18.00. In average, analysts' outlook on EPZM price target is negative, reducing the target by a -24.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, Epizyme failed to meet the forecasts of the experts and posted a frightening EPS of $-0.29 per share when experts were expecting $-0.49.
EPZM earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, Epizyme annual sales climbed a super good 117.00% to $21.70 M dollars from $10.00 marked in 2017. When comparing 2018 vs 2017, in line, profit margin (that is, the net income divided by revenues) skyrocketed a 773.37% to -569.72%.

EPZM annual Sales and Income evolution
2013$68 M-$-3.48 M-5.1%-
2014$41 M-39.53%$-55.01 M-132.8%1,480.60%
2015$2.56 M-93.82%$-132.38 M-5170.9%140.66%
2016$8.01 M212.77%$-110.21 M-1376.4%-16.74%
2017$10 M24.89%$-134.31 M-1343.1%21.86%
2018$22 M117.00%$-123.63 M-569.7%-7.95%

Quarterly financial results

Epizyme posted $9.70 M in revenues for 2018-Q4, a inf% improvement compared to previous quarter. Reported quarter earnings marked $-22.95 million with a profit margin of -236.55%. Profit margin remained stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Epizyme sales marked an amazing increase and boosted a inf%.
EPZM quarterly Sales and Income evolution
2017-Q2$10 M-$-28.02 M-280.2%-
2018-Q2$12 M20.00%$-29.13 M-242.7%3.95%
2018-Q4$10 M-19.17%$-22.95 M-236.5%-21.23%

Epizyme ownership

When you are planning to invest in shares of a company, it's worth to have a look its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Epizyme, 4.94% of all outstanding shares are owned by its staff.

Bearish positions for EPZM stock account 0.00%, no big difference from last month.

For a better understanding, the following table shows ownership data compared to other related stocks:

Market cap$922.7 M$149.4 B$67.1 B$0.0 M$102.0 B
Total shares69.5 M1,760.0 M701.0 M0.0 M2,490.0 M
Float shares76.3 M1,750.0 M706.3 M13.9 M2,440.0 M
  - Institutional holdings (%)93.2%76.5%77.6%8.1%11.0%
  - Insider holdings (%)4.9%0.7%0.2%16.9%0.0%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Epizyme summary

Thursday, August 22nd, 2019
Day range$13.02 - $13.60
Previous close$13.58
Session gain-2.21%
Average true range$0.77
50d mov avg$13.03
100d mov avg$12.92
200d mov avg$11.23
Daily pattern
Weekly pattern

Epizyme performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We compared Epizyme against , Celgene, Dare Bioscience, GlaxoSmithKline, Novartis and Seattle Genetics in the following table:
DAREDare Bioscience-9.20%-7.06%-23.30%
SGENSeattle Genetics13.34%10.01%5.05%

Epizyme competitors

One check before investing in any stock is to review a list of its competitors, in this case for Epizyme. We chose 6 companies as Epizyme competitors as they are in the same industry or have similar market objectives.